Skip to content

PCRSG Article Exclusion Criteria

All Accepted Treatments:

  1. Radical Prostatectomy- Open
  2. Radical Prostatectomy- Robotic
  3. Std EBRT
  4. Hypofx EBRT
  5. Ultrahypofx EBRT
  6. Protons
  7. LDR Brachy
  8. HDR Brachy
  9. EBRT + LDR Brachy
  10. EBRT + HDR Brachy
  11. ADT + Std EBRT
  12. ADT + Hypofx EBRT
  13. ADT + Ultrahypofx EBRT
  14. ADT + LDR Brachy
  15. ADT + HDR Brachy
  16. ADT + EBRT + LDR Brachy
  17. ADT + EBRT + HDR Brachy
  18. Cryotherapy
  19. HIFU

Study Acceptance/Rejection Key Code:

  1. Accepted
  2. Risk Groups - No stratification into recognizable Pre-Treatment Risk Groups: Low, Intermediate, and High Risk by either D’Amico, Zelefsky or NCCN stratification. The risk group must be maintained after treatment.
  3. Endpoint - None of the following endpoints evaluated: BRFS (biochemical relapse free survival) standard endpoint ASTRO, Phoenix, and PSA < 0.2 (surgery), OS (overall survival), MFS (metastasis free survival), and CSS (cause specific survival).
  4. Staging - No Pathologic staging. Must be pretreatment clinical staging. Pts cannot be eliminated or excluded from future analysis because of an unfavorable feature, such as positive margin or positive lymph nodes.
  5. EBRT Doses - < 72 Gy standard fractionation IMRT/or 3D conformal.
  6. Treatment modalities – does not fall into one of the above categories (see list above.)
  7. Peer reviewed journal articles – Not published in a peer reviewed journal. Presentations and/or posters do not meet criteria.
  8. Number of patients - Low-Risk < 100 patients. Intermediate-Risk < 100 patients. High-< 50 patients.
  9. Median follow up - < 5 years